An observational study in Knee Replacement Arthroplasty, Fibrosis and Dupuytren's Disease, sponsored by University Hospital Pellenberg. Status unknown. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-11-19.
Sponsored by University Hospital Pellenberg · Observational
At the standard follow-up moment one year after primary TKA for gonarthrosis, all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.
This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis. For both groups, the range of motion (ROM) of the operated knee at 3 and 6 months will be retrieved in the charts, the ROM at 12 months will be measured at that time. Also, additional procedures performed to increase ROM postoperatively will be retrieved from the charts (e.g. continuous passive motion, mobilization under anesthesia). Other causes for knee stiffness will have to be recorded, since these will be the most important exclusion criteria.
In the patients with clear signs of finger contractures, any impression of increase of contracture over the past 12 months will be recorded.
76 studies on the registry are indexed under Dupuytren Contracture; 16 are open to participants now.
This study's planned enrollment of 60 is below the median of 80 across 19 observational studies indexed under Dupuytren Contracture.
Browse Dupuytren Contracture studies →University Hospital Pellenberg is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients who undergo a total knee arthroplasty for primary gonarthrosis at a minimal age of 50 years showing signs of fibrosis diathesis at presentation can be included. Patients who do not show signs of fibrosis diathesis will serve as a control group.
Exclusion Criteria:
all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis. This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis.
Procedure: Total knee arthroplasty
all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis. This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis.
Procedure: Total knee arthroplasty
Range of movement of the operated knee at 12 months postoperatively
Time frame: 12 months
Additional procedures/interventions to gain motion
Time frame: 12 months
- Increase of contracture or appearance of the nodules and contractures in the hand after the knee surgery.
Time frame: 12 months
KSS score for knee function
Time frame: 12 months
No study locations are listed for this record.
This study is status unknown, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Pellenberg